Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention
Citation
Erdim R, Erciyes D, Görmez S, Karabay KO, Catakoğlu AB, Aytekin V, Demiroğlu C, Gülbaran M. Erdim R1, Erciyes D, Görmez S, Karabay KO, Catakoğlu AB, Aytekin V, Demiroğlu C, Gülbaran M. Anadolu Kardiyoloji Dergisi. 2010; 10(4):340-345. doi: 10.5152/akd.2010.093.Abstract
OBJECTIVE: The purpose of this study was to compare the intravenous bolus dose of tirofiban with intracoronary bolus dose in primary percutaneous coronary intervention (PCI) with regard to in hospital and six months clinical outcomes and peak cardiac enzyme levels.
METHODS: We retrospectively examined 84 ST elevation myocardial infarction (STEMI) patients who underwent primary PCI from March 2006 to February 2007. All patients received the systemic bolus dose of tirofiban 10 mcg/kg either via intracoronary (IC) or intravenous (IV) route, followed by a 36 hours of IV infusion at 0.15 mcg/kg/min. Thirty six patients in IC group were compared with 48 patients in IV group in terms of peak cardiac enzyme levels, in-hospital and six months major adverse cardiac events (MACE) rates (death, myocardial infarction and repeat revascularization). Fisher's exact test, Yates Chi-square, unpaired Student's t-test and Mann-Whitney U test were used for statistical analysis.
